Havas Health adds PR agency Just:: Health Communications in bid to expand its global footprint.
A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again
Supreme Court affirmed the legality of the Affordable Care Act for a second time on Thursday
Just landed a new job? You've got 100 days to make an impression. Here are some suggestions.
Fourth and fifth members of network add healthcare advertising and PR expertise.
AbbVie says curative effects hold whether Viekira Pak used with or without ribavirin; House Republicans vote to eliminate IPAB; analyst sets high price target for Alexion.
The consumer-insights firm said it's debuting a listening feature that will make it harder for pharma to ignore Twitter, Reddit and the other big social platforms.
The promise of an Opdivo/Yervoy combination, now awaiting FDA approval, has more to do with payer strategy than efficacy, analysts say.
Adults dominate the ADHD prescription category; the FDA approved The Medicine Company's anticlotting drug 10 years after issuing a CRL; a survey shows personalized content can build consumer goodwill
Clinical trial results for experimental antidotes to oral anticoagulants Pradaxa and Eliquis indicate they reverse blood thinners in a short time.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.